Redeye comments on Dala Energi’s Q2 report, which was again characterised by the strategic restructu...
Cereno Scientific’s Q225 results demonstrated steady progress across its clinical assets, with encou...
In Q2, Prolight reported initial positive data from its ongoing whole blood study at St Thomas’ Hosp...
The offering represents a 55% discount from yesterday's trading, and we find that Hargreaves has no ...
Redeye updates its estimates following Fable Media Group’s Q2 report, which came in largely in line ...
Redeye comments on FluoGuide’s Q2 2025 report. The company’s recent progress update mostly aligned w...
Redeye comments on the now confirmed partnering with industry giant Quest Diagnostics for channel co...
Alzinova is a Sweden-based clinical-stage biopharmaceutical company seeking to advance treatments fo...
Redeye comments on Jumpgate’s Q2 report, which was broadly in line with our estimates, with the exce...
Redeye comments on Nekkar’s Q2 report, that presented mixed Q2 figures during a relatively slow peri...
Redeye comments on Fable Media Group’s Q2 results, aligning with the preliminary figures and our est...
Train Alliance levererade ett starkt andra kvartal med stigande intäkter och en förbättrad rörelsema...
Redeye comments on GiG’s Q2-results which were in line with expectations and the preliminary outcome...
Nanexa presented strong validation of its PharmaShell technology during the first half of 2025, with...
Redeye provides an in-depth review of AcouSort’s Q2 report and activities during and after the quart...
Redeye is impressed by the strong delivery from GomSpace during the last two quarters, posting stell...
Redeye initiates coverage of BICO, a leading player in the bioconvergence space.
Redeye makes a correction to our estimates, slightly impacting our fair value range.
* Enedo drove the 6% Q2 adj. EBITA miss while Inission beat by 4% * 1.
* Europe and other markets continue to perform, North America less so * We reset our expectations-po...
